Panelists discuss how the IMscin001 trial findings established subcutaneous atezolizumab noninferiority with comparable efficacy and safety to intravenous (IV) formulation while highlighting operational challenges, including creating multiple electronic medical record (EMR) order sets, standardizing injection times and volumes across products, and addressing nursing workflow considerations during the 2- to 10-minute injection periods.

Learn the critical factors in determining prophylaxis for venous thromboembolism, a frequent and serious complication for patients with cancer.

Following imlunestrant’s approval, Komal Jhaveri, MD, FACP, compares the oral SERD to its counterpart, elacestrant, in terms of composition and trials.

AI-driven decision support can ease oncologists’ workloads and streamline care without reducing autonomy.

The FDA has granted approval to adjuvant cemiplimab treatment for patients with high-risk cutaneous squamous cell carcinoma after surgery and radiation.

CRS and ICANS were observed in 48% and 16%, respectively, of patients with ES-SCLC who received tarlatamab, according to real-world data.

A network to connect patients with unused medications with patients in need brought $18 million of free cancer medication while reducing drug waste.

In the phase 3 SURPASS-ET trial, ropeginterferon alfa-2b outperformed anagrelide as second-line therapy for high-risk essential thrombocythemia.

Panelists discuss how the subcutaneous nivolumab data demonstrate reassuring safety with minimal grade 3/4 events, how pharmacokinetic equivalency across varied patient weights supports flat dosing, how immune-mediated adverse events remain unpredictable and not dose dependent, and how patients appreciate the mild, transient injection site reactions.

Panelists discuss how the CheckMate-67T trial established noninferiority of subcutaneous nivolumab to intravenous (IV) nivolumab through pharmacokinetic end points, comparable efficacy (24% vs 18% overall response rate [ORR]), similar safety profiles with mostly mild injection site reactions, and FDA approval across all monotherapy indications.

Cassie A. Gray, MS, RN, OCN, CHPN, explains how early palliative care integration benefits patients with advanced cancer.

Heather J. Jackson, PhD, APRN, FNP-BC, NEA-BC, FAA-NP, shared a review of supportive oncology practices at the 2025 School of Nursing Oncology.

The FDA has approved lurbinectedin plus atezolizumab for the treatment of extensive-stage small cell lung cancer following induction therapy with atezolizumab.

Jeneth Aquino, DNP, FNP-BC, explains that using ctDNA to guide a patient’s next steps can provide clarity in the treatment process.

The addition of atezolizumab to chemoradiation led to meaningful improvements to quality of life for patients with small cell lung cancer.

Heather Jackson, PhD, APRN, FNP-BC, NEA-BC, FAA-NP, explains the utility of a holistic approach to oncology care.

Panelists discuss how subcutaneous checkpoint inhibitors offer benefits through reduced wait times, potential for injection rooms or examination room administration, streamlined pharmacy workflows, improved patient quality of life by making them feel less like “cancer patients,” and opportunities for home-based care delivery in underserved areas.

Panelists discuss how intravenous (IV) administration of immune checkpoint inhibitors creates challenges, including infusion chair bottlenecks, lengthy multistep clinic visits, difficult venous access over time, and significant time burdens for both patients and health care systems.

Courtney Moore, APRN, FNP-C, OCN, discusses planning beyond first-line CDK4/6 inhibitors and supportive care strategies for patients with HR+/HER2– disease.

Subcutaneous daratumumab is well tolerated, but ongoing immune monitoring is key to managing infection risk in patients with multiple myeloma.

An LED-based intraoral device for photobiomodulation therapy was safe and reduced severe oral mucositis in patients with head and neck cancers.

The REMS program for vandetanib in the treatment of patients with medullary thyroid cancer has been removed by the FDA.

Leaders in oncology nursing and advanced practice spotlight the essential role of advanced practice providers in oncology.

Melissa Rikal, FNP-BC, AOCNP, explains how ctDNA can inform prognosis, monitor disease progression, and guide treatment decisions in oncology.

The FDA has approved imlunestrant for the treatment of patients with ESR1-mutated ER+, HER2- metastatic breast cancer.